Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$846M |
| 2 |
JD.com
JD
|
+$782M |
| 3 |
Dollar General
DG
|
+$647M |
| 4 |
Monster Beverage
MNST
|
+$324M |
| 5 |
NXP Semiconductors
NXPI
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$668M |
| 2 |
Mondelez International
MDLZ
|
+$528M |
| 3 |
Alibaba
BABA
|
+$457M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$409M |
| 5 |
CELG
Celgene Corp
CELG
|
+$403M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.97% |
| 2 | Consumer Discretionary | 16.01% |
| 3 | Technology | 12.95% |
| 4 | Communication Services | 12.43% |
| 5 | Financials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Pacira BioSciences
PCRX
$1.04B
| $118M | 0.11% |
1,672,608
-1,174,059
| -41% | -$92.5M |
|
177
Liberty Global Class C
LBTYK
$3.5B
| $117M | 0.11% |
2,865,080
+324,663
| +13% | +$13.4M |
|
178
Flowserve
FLS
$8.94B
| $117M | 0.11% |
2,222,072
-79,252
| -3% | -$4.42M |
|
179
CVS Health
CVS
$135B
| $117M | 0.11% |
1,112,418
-132,212
| -11% | -$13.5M |
|
|
CAM
180
DELISTED
CAMERON INTERNATIONAL CORPORATION
CAM
| $116M | 0.11% |
2,220,632
-5,273
| -0.2% | -$273K |
|
|
WCC
181
WESCO International
WCC
$15.1B
| $116M | 0.11% |
1,686,234
-88,273
| -5% | -$6.33M |
|
182
Edison International
EIX
$30.3B
| $115M | 0.11% |
2,069,187
-463,730
| -18% | -$27.9M |
|
183
Fortinet
FTNT
$112B
| $115M | 0.11% |
13,900,250
-9,833,960
| -41% | -$76.4M |
|
184
Alnylam Pharmaceuticals
ALNY
$38.3B
| $114M | 0.1% |
953,647
+7,800
| +0.8% | +$932K |
|
185
Align Technology
ALGN
$12.9B
| $114M | 0.1% |
1,822,188
+133,646
| +8% | +$7.89M |
|
186
United Airlines
UAL
$38.8B
| $114M | 0.1% |
2,152,770
-3,091,318
| -59% | -$179M |
|
187
Cooper Companies
COO
$14.2B
| $113M | 0.1% |
2,547,056
+837,472
| +49% | +$37.7M |
|
|
MFRM
188
DELISTED
MATTRESS FIRM HLDG CORP COM STK (DE)
MFRM
| $113M | 0.1% |
1,855,101
-355,691
| -16% | -$21.7M |
|
189
Axalta
AXTA
$7.45B
| $112M | 0.1% |
+3,389,029
| New | +$112M |
|
190
Phillips 66
PSX
$82.9B
| $111M | 0.1% |
1,379,302
-1,414
| -0.1% | -$112K |
|
191
Dominion Energy
D
$62B
| $110M | 0.1% |
1,641,394
-110,243
| -6% | -$7.76M |
|
192
Church & Dwight Co
CHD
$23.7B
| $108M | 0.1% |
2,661,716
-94,308
| -3% | -$3.95M |
|
193
F5
FFIV
$22B
| $107M | 0.1% |
887,588
-94,382
| -10% | -$11.6M |
|
194
Acadia Pharmaceuticals
ACAD
$4.51B
| $106M | 0.1% |
2,521,324
+40,103
| +2% | +$1.55M |
|
195
Burlington
BURL
$23.4B
| $105M | 0.1% |
2,054,628
+1,256,102
| +157% | +$67.1M |
|
196
Medtronic
MDT
$112B
| $103M | 0.09% |
1,395,889
-431,580
| -24% | -$33M |
|
197
Teva Pharmaceuticals
TEVA
$40.4B
| $103M | 0.09% |
1,746,848
-343,225
| -16% | -$21.2M |
|
198
Sprouts Farmers Market
SFM
$7.44B
| $103M | 0.09% |
3,814,267
+9,291
| +0.2% | +$285K |
|
199
Patterson-UTI
PTEN
$3.54B
| $102M | 0.09% |
5,398,340
+2,558,706
| +90% | +$53.1M |
|
200
Bath & Body Works
BBWI
$3.97B
| $101M | 0.09% |
1,451,574
-51,564
| -3% | -$3.7M |
|
Similar funds
Jennison Associates's Q2 2015 Portfolio in Review
As of Q2 2015, Jennison Associates held 801 positions worth $109B, down 0.05% from $109B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Jennison Associates's Q2 2015 filing shows 92 new, 315 increased, 305 reduced and 72 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M. The largest sale was Union Pacific, an estimated $668M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Technology.
- Jennison Associates's largest Q2 2015 buy was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M.
- Jennison Associates added most to JD.com in Q2 2015, an estimated $782M increase.
- Jennison Associates's biggest Q2 2015 reduction was Union Pacific, cutting an estimated $668M.
- Jennison Associates fully exited Perrigo in Q2 2015, selling an estimated $204M.
- Jennison Associates's ten largest holdings make up 21% of its $109B portfolio in Q2 2015.
- Jennison Associates opened 92 new positions and closed 72 in Q2 2015.
- Jennison Associates's portfolio value fell 0.05% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2015, filed 3 Aug 2015.